Sun Pharma agrees to supply at MFN pricing to U.S. medicaid programmes
The U.S. is the company’s largest market for innovative medicines and a cornerstone of its long-term growth strategy, generating approximately 27% of the company’s global revenue.
We haven't written up this one. The Hindu - Sci-Tech has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.